Showing 51-60 of 2111 results for "".
Robert Grant Steps Down at Alphaeon; Skin Cancer Special Edition
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-robert-grant-steps-down-at-alphaeon-skin-cancer-special-edition/18595/Robert Grant is no longer CEO of lifestyle healthcare company Alphaeon. Mr. Grant founded Alphaeon in 2013 as a wholly owned subsidiary of Strathspey Crown LLC, a private equity firm located in Newport Beach, CA, where he serves as Chairman. Also in this issue, a closer look at skin cancer. May is SDerm Insider: Navigating Office Politics
https://practicaldermatology.com/topics/practice-management/derm-insider-navigating-office-politics/18993/In this edition of Derm Insider, host Neal Bhatia, MD speaks with practice management experts about the complex inner workings of an office environment, as well as the role of physicians in managing precarious situations regarding employees. Offering advice for maneuvering these situations, guests SLight & Bright: A new treatment to illuminate your practice
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/light-bright-a-new-treatment-to-illuminate-your-practice/19746/Join Matthew Mahlberg, MD as he introduces the new Light & Bright treatment. Using the patented Ellipse IPL and Frax 1550 technologies on the Nordlys system, the Light & Bright treatment reduces pigmentation & redness and improves textural irregularities. Hear the results of a clinical sDupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects sActinic Keratosis: Therapy Overview
https://practicaldermatology.com/topics/skin-cancer-photoprotection/actinic-keratosis-therapy-overview/19732/Joel Cohen, MD interviews George Martin, MD about the latest developments in actinic keratosis. Dr. Martin said he is eagerly awaiting regulatory review of tirbanibulin, which showed promising results in clinical trials. The two also discuss practical tips and nuances of using 5FU in practice. *Be sThe Microbiome in Atopic Dermatitis: Where Are We Now?
https://practicaldermatology.com/topics/atopic-dermatitis/the-microbiome-in-atopic-dermatitis-where-are-we-now/23746/It seems increasingly likely that microbes will play a central role in understanding AD and its treatments.Comorbidities in Immune-mediated Skin Disorders: What’s Coming
https://practicaldermatology.com/issues/january-february-2025/comorbidities-in-immune-mediated-skin-disorders-whats-coming/32968/Comorbidities in immune-mediated skin disorders (IMSDs) occur frequently and have a significant impact on disease severity, treatment, prognosis, and quality of life.Staphylococcus aureus and Atopic Dermatitis: Unweaving a Tangled Web
https://practicaldermatology.com/topics/general-topics/staphylococcus-aureus-and-atopic-dermatitis-unweaving-a-tangled-web/22083/Though the relationship is not fully understood, it points the way to potential treatments.The Pitfalls of Excessive Electronic Communication: “I Didn’t See That Email”
https://practicaldermatology.com/topics/practice-management/the-pitfalls-of-excessive-electronic-communication-i-didnt-see-that-email/23132/All communication should be thoughtful and intentional. Where does technology fit in?“OK…if you say so”
https://practicaldermatology.com/topics/skin-cancer-photoprotection/okif-you-say-so/20652/